Bulk manufacturing facility of Incepta will be useful for Covid-19 vaccine: DGDA chief

At this time of Covid-19, the bulk manufacturing facility of Incepta Vaccine Ltd may play a big role for Bangladesh and other countries as well when the vaccine is released, said Major General Md Mahbubur Rahman, chief of the Directorate General of Drug Administration (DGDA), yesterday.

The world class plant of Incepta Vaccine has achieved the ability to produce life-saving international standard vaccines by following Good Manufacturing Practice (GMP) standards, he said on a visit to the facility at Zirabo, Savar.

Chief Operating Officer (COO) of Incepta Mahbubul Karim said the plant has a capacity to produce 180 million doses of vaccines a year.

"That is good news for all of us. When the bulk requirement of the Covid-19 vaccine will be created all over the world, we are hopeful that world community will use this plant," the COO added.

Incepta Vaccine began its journey in 2011 and has successfully produced and marketed 13 vaccines along with immunoglobulins such as those for Rabies, Hepatitis-B, Hepatitis-A, Typhoid, Tetanus, and Meningitis.

The self-sufficient technology of Incepta Vaccine is able to produce both bacterial and viral antigens, and ensure the bulk production of any vaccine through technology transfer.